RVMD Annual Cash & Cash Equivalents
$696.15 M
+$534.74 M+331.29%
31 December 2023
Summary:
As of January 22, 2025, RVMD annual cash & cash equivalents is $696.15 million, with the most recent change of +$534.74 million (+331.29%) on December 31, 2023. During the last 3 years, it has risen by +$591.88 million (+567.65%). RVMD annual cash & cash equivalents is now at all-time high.RVMD Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVMD Quarterly Cash And Cash Equivalents
$201.26 M
-$74.45 M-27.00%
30 September 2024
Summary:
As of January 22, 2025, RVMD quarterly cash and cash equivalents is $201.26 million, with the most recent change of -$74.45 million (-27.00%) on September 30, 2024. Over the past year, it has dropped by -$87.17 million (-30.22%). RVMD quarterly cash and cash equivalents is now -71.09% below its all-time high of $696.15 million, reached on December 31, 2023.RVMD Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVMD Cash And Cash Equivalents Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +331.3% | -30.2% |
3 y3 years | +567.6% | +55.8% |
5 y5 years | +900.4% | +93.0% |
RVMD Cash And Cash Equivalents High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +541.6% | -71.1% | +106.1% |
5 y | 5-year | at high | +4078.8% | -71.1% | +1108.1% |
alltime | all time | at high | +7567.7% | -71.1% | +1108.1% |
Revolution Medicines Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $201.26 M(-27.0%) |
June 2024 | - | $275.71 M(-4.4%) |
Mar 2024 | - | $288.43 M(-58.6%) |
Dec 2023 | $696.15 M(+331.3%) | $696.15 M(+94.2%) |
Sept 2023 | - | $358.40 M(-5.8%) |
June 2023 | - | $380.33 M(-11.0%) |
Mar 2023 | - | $427.22 M(+164.7%) |
Dec 2022 | $161.41 M(+48.8%) | $161.41 M(-9.8%) |
Sept 2022 | - | $178.94 M(+69.2%) |
June 2022 | - | $105.78 M(+8.3%) |
Mar 2022 | - | $97.67 M(-10.0%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2021 | $108.50 M(+4.1%) | $108.50 M(-16.0%) |
Sept 2021 | - | $129.15 M(-34.0%) |
June 2021 | - | $195.60 M(-44.4%) |
Mar 2021 | - | $351.60 M(+237.2%) |
Dec 2020 | $104.27 M(+525.9%) | $104.27 M(+60.7%) |
Sept 2020 | - | $64.87 M(+170.6%) |
June 2020 | - | $23.98 M(-86.9%) |
Mar 2020 | - | $182.67 M(+996.5%) |
Dec 2019 | $16.66 M(-76.1%) | $16.66 M(-23.7%) |
Sept 2019 | - | $21.82 M(-68.6%) |
Dec 2018 | $69.59 M(+666.5%) | $69.59 M |
Dec 2017 | $9.08 M | - |
FAQ
- What is Revolution Medicines annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Revolution Medicines?
- What is Revolution Medicines annual cash & cash equivalents year-on-year change?
- What is Revolution Medicines quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Revolution Medicines?
- What is Revolution Medicines quarterly cash and cash equivalents year-on-year change?
What is Revolution Medicines annual cash & cash equivalents?
The current annual cash & cash equivalents of RVMD is $696.15 M
What is the all time high annual cash & cash equivalents for Revolution Medicines?
Revolution Medicines all-time high annual cash & cash equivalents is $696.15 M
What is Revolution Medicines annual cash & cash equivalents year-on-year change?
Over the past year, RVMD annual cash & cash equivalents has changed by +$534.74 M (+331.29%)
What is Revolution Medicines quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RVMD is $201.26 M
What is the all time high quarterly cash and cash equivalents for Revolution Medicines?
Revolution Medicines all-time high quarterly cash and cash equivalents is $696.15 M
What is Revolution Medicines quarterly cash and cash equivalents year-on-year change?
Over the past year, RVMD quarterly cash and cash equivalents has changed by -$87.17 M (-30.22%)